Neurogene (NASDAQ:NGNE) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright assumed coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research note released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $45.00 price target on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2023 earnings at ($1.66) EPS, FY2023 earnings at ($7.82) EPS, Q1 […]
More Stories
Scotiabank Increases Air Canada (TSE:AC) Price Target to C$24.00
Air Canada (TSE:AC – Free Report) had its price objective raised by Scotiabank from C$22.00 to C$24.00 in a research...
Enerflex (TSE:EFX) Given New C$12.00 Price Target at Raymond James
Enerflex (TSE:EFX – Free Report) had its price objective increased by Raymond James from C$11.75 to C$12.00 in a research...
Entravision Communications Co. (NYSE:EVC) Sees Significant Decrease in Short Interest
Entravision Communications Co. (NYSE:EVC – Get Free Report) was the recipient of a large decline in short interest in September....
BMO Capital Markets Downgrades Saputo (TSE:SAP) to Market Perform
BMO Capital Markets lowered shares of Saputo (TSE:SAP – Free Report) from an outperform rating to a market perform rating...
Arhaus (NASDAQ:ARHS) Downgraded to “Hold” at Craig Hallum
Craig Hallum cut shares of Arhaus (NASDAQ:ARHS – Free Report) from a buy rating to a hold rating in a...
CGI (NYSE:GIB) Raised to Outperformer at CIBC
CIBC upgraded shares of CGI (NYSE:GIB – Free Report) (TSE:GIB.A) from a neutral rating to an outperformer rating in a...